The MADI plication - a revised technique

Article

A comparison study of patients who underwent minimally invasive strabismus surgery (MISS) with a total dissection of the plicated part of the rectus muscle and those who had MISS where only a marginal dissection was performed.

Surgical techniques for reducing the conjunctival incision size in minimally invasive strabismus surgery (MISS) have been developed (see New MISS technique is a hit) helping to drastically reduce tissue trauma and postoperative discomfort for patients. Over the years strabismologists have used a number of access techniques for horizontal muscle recession, plication or resection.1-5

"I wanted to find a new, even less traumatic minimally invasive plication technique using no spatula, compared to the standard MISS procedure," explained Dr Mojon. "So, rather than undertake a total dissection (TODI) I performed only a marginal dissection (MADI) of the plicated part of the muscle."

The study

Exclusions

For those who underwent both MADI and TODI plication but who required revision surgery or retroequitorial fixation sutures, vertical rectus muscle surgery or simultaneous surgery of an oblique muscle were excluded.

Follow-up

Orthoptic examinations were conducted postoperatively on Day 1 and after 6 months for both groups of patients. Only those with a complication or not referred by an ophthalmologist were seen at Dr Mojon's department. The remainder were followed up by referring ophthalmologists in between Day 10 and Week 4.

Measured outcomes

"The outcomes examined included alignment, vision variations, binocular single vision, refraction, conjunctival abnormalities, dose-response relationship and number and types of complications experienced during the six months following the operation," said Dr Mojon.

The modified technique for MADI MISS

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.